Publication-Grade Peptides: Selected Examples from the Literature

Publication-Grade Peptides: Selected Examples from the Literature

LifeTein peptides have been cited in many peer-reviewed publications, including studies requiring long peptide synthesis, fluorescent labeling, phosphopeptides, biotinylated peptides, cyclic peptides, and other challenging custom formats. This page highlights representative peptide capability areas rather than trying to function as a broad publications archive.

Featured example: Nature Communications (2026)

In a recent study on IRF2BPL, LifeTein synthesized two difficult custom peptides: a 54 amino acid peptide with N-terminal acetylation, C-terminal amidation, and >95% purity, and a 75 amino acid peptide with an N-terminal FITC tag linked through a 6-aminohexanoic acid (Ahx) spacer, C-terminal amidation, and >90% purity.

Selected Capability Areas

Long peptides and difficult sequences

Fluorescently labeled peptides

N-terminal acetylation and C-terminal amidation

Biotin, Ahx, and linker-modified peptides

Phosphopeptides and PTM-containing peptides

Cyclic and constrained peptide formats

Peptides for protein interaction studies

Peptide tools for antibody generation and validation

For the broader references archive, see Selected Publications and Success Stories.

Featured Publications

Nature Communications, 2026, NEDAMSS syndrome-related truncating and missense mutations are associated with aberrant liquid-liquid phase separation of IRF2BPL

LifeTein synthesized a very long 54 aa peptide spanning the human IRF2BPL HCD core region (a.a. 395–448) with N-terminal acetylation, C-terminal amidation, and purity >95%. The same study also used a 75 aa peptide spanning the ZnF region (a.a. 1–75) with an N-terminal FITC tag linked through a 6-aminohexanoic acid (Ahx) spacer, C-terminal amidation, and purity >90%.

PNAS, Quantitative Structural Assessment of Graded Receptor Agonism

A peptide containing an LXXLL nuclear receptor interaction motif from TRAP220/MED1/DRIP205 was synthesized with an N-terminal FITC label, a six-carbon linker (Ahx), and an amidated C-terminus by LifeTein.

Nature, Monitoring T cell–dendritic cell interactions in vivo by intercellular enzymatic labelling

Biotin–aminohexanoic acid–LPETGS and SELPETGG peptides were purchased from LifeTein, illustrating biotinylated and spacer-modified peptide formats used in advanced biological studies.

Nature Communications, A structural mechanism for directing corepressor-selective inverse agonism of PPARγ

A peptide NCoR1 containing an N-terminal biotin label and an amidated C-terminus for stability was synthesized by LifeTein.

Cell, HIV-1 Integrase Binds the Viral RNA Genome and Is Essential during Virion Morphogenesis

The cyclic peptide L50 peptide: Cyclo-(-Arg-Val-Arg-Thr-Arg-Gly-Lys-Arg-Arg-Ile-Arg-Arg-DPro-Pro-) was purchased from LifeTein, illustrating constrained peptide capability.

Nature, EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2

LifeTein designed and synthesized a series of phosphorylated peptides, and the peptides were then used for phospho-specific antibody production.

Cell, A Cell-Penetrating Scorpion Toxin Enables Mode-Specific Modulation of TRPA1 and Pain

The Wasabi Receptor Toxin, its mutants, biotinylated variants, and Alexa Fluor 488-conjugated variants were synthesized by LifeTein, illustrating advanced labeled peptide capability.

Selected publication examples by capability

These examples are compiled from publicly available literature and are updated periodically. Many additional studies have used LifeTein materials but may not be included in this list.

Case study Europe PMC • 2026-02-27 NEDAMSS syndrome-related truncating and missense mutations are associated with aberrant liquid-liquid phase separation of IRF2BPL. long peptide Context: Featured example: long peptide synthesis and FITC-Ahx peptide labeling for IRF2BPL research.

Case study Europe PMC • 2025-10-08 A fluorescent bead-based multiplex assay for the detection of <i>Brucella</i> sp. specific antibodies in canine serum. fluorescent peptide antibody-related Context: Representative example involving fluorescent peptide, antibody-related.

Case study Europe PMC • 2024-10-28 Discovery of peptides for ligand-mediated delivery of mRNA lipid nanoparticles to cystic fibrosis lung epithelia. delivery / CPP-related nucleic acid-related Context: Representative example involving delivery / CPP-related, nucleic acid-related.

Case study Europe PMC • 2026-03-13 Crystal structures reveal phosphorylation-dependent disruption of the heat shock protein 70-CHIP interface: A compensatory G132N variant restores binding affinity. phosphopeptide / PTM peptide Context: Representative example involving phosphopeptides, phosphorylation-related targets, or PTM-directed peptide tools.

Case study Europe PMC • 2026-04-26 From randomness to recognition: modeling the evolution of DNA sequence information during enrichment for binding. nucleic acid-related Context: Representative example involving nucleic acid-related.

Case study Europe PMC • 2026-04-24 Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). nucleic acid-related Context: Representative example involving nucleic acid-related.

Case study Europe PMC • 2026-03-18 Thermodynamic prediction of RNA cellular activity from sequence via conformational ensembles. nucleic acid-related Context: Representative example involving nucleic acid-related.

Case study Europe PMC • 2026-03-02 Retrotransposon activation during spermatogenesis achieves massive ecDNA biogenesis but rare integration. nucleic acid-related Context: Representative example involving nucleic acid-related.

Case study Europe PMC • 2025-12-20 Kinetochore mutations and histone phosphorylation pattern changes accompany holo- and macro-monocentromere evolution. phosphopeptide / PTM peptide Context: Representative example involving phosphopeptides, phosphorylation-related targets, or PTM-directed peptide tools.

Case study Europe PMC • 2025-06-06 Sprinkling in extra validation for high-value PTMs and therapeutic Abs with MILKSHAKE Western blots and Sundae ELISAs. phosphopeptide / PTM peptide Context: Representative example involving phosphopeptide / PTM peptide.

Case study Europe PMC • 2025-01-14 Structure of the human autophagy factor EPG5 and the molecular basis of its conserved mode of interaction with Atg8-family proteins. fluorescent peptide Context: Representative example involving fluorescent peptide.

Case study Europe PMC • 2025-10-24 DNA-damage dependent isoform switching modulates RIF1 DNA repair complex assembly and phase separation. nucleic acid-related Context: Representative example involving nucleic acid-related.

Case study Europe PMC • 2025-09-26 A domain-swapped CaMKII conformation facilitates linker-mediated allosteric regulation. linker-modified peptide Context: Representative example involving linker-modified peptide.

Case study Europe PMC • 2025-08-27 Evaluating the effect of the mitochondrial alternative peptide MTALTND4 on gene expression. nucleic acid-related Context: Representative example involving nucleic acid-related.

Case study Europe PMC • 2025-04-26 In Vivo Cytosolic Delivery of Biomolecules into Neurons for Super-Resolution Imaging and Genome Modification. delivery / CPP-related Context: Representative example involving delivery / CPP-related.

Related pages

For the broader publication archive, see Selected Publications and Success Stories. For service pages connected to these capabilities, see Long Peptide Synthesis, FITC Peptide Synthesis, and Peptide Synthesis Services.

We use essential cookies to make our site work. With your consent, we may also use non-essential cookies to improve user experience and analyze website traffic. You can accept all cookies or continue with essential cookies only. See our Cookie Policy.